Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

25 arms have a reported figure.

Avapritinib 4

Avapritinib

Avapritinib 300 or 400 mg, PDGFRA exon 18

300 or 400 mg · Single arm

unresectable or metastatic GIST with PDGFRA exon 18 mutation (n = 43)

overall response rate (independent review): 84%, median follow up 10.6 months

NAVIGATOR · NCT02508532

Avapritinib

Avapritinib, PDGFRA D842V subgroup

300 or 400 mg · Single arm

PDGFRA D842V (n = 38)

overall response rate (independent review): 89%, median follow up 10.6 months

NAVIGATOR · NCT02508532

Avapritinib

Avapritinib 300 mg

300 mg · ITT

3L or later GIST (n = 240)

Comparator: regorafenib 160 mg

median progression-free survival: 4.2 months, primary analysis

progression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055

objective response rate: 17.1%, primary analysis

VOYAGER · NCT03465722

Avapritinib

Regorafenib 160 mg

160 mg · ITT

3L or later GIST (n = 236)

median progression-free survival: 5.6 months, primary analysis

objective response rate: 7.2%, primary analysis

VOYAGER · NCT03465722

Bezuclastinib + Sunitinib 2

Bezuclastinib + Sunitinib

Bezuclastinib 600 mg + sunitinib 37.5 mg

600 mg + 37.5 mg · ITT

GIST after imatinib (n = 204)

Comparator: sunitinib 37.5 mg

median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025

progression-free survival hazard ratio vs sunitinib: 0.5 HR, data cutoff 09.30.2025

objective response rate (BICR): 46%, data cutoff 09.30.2025

PFS2 hazard ratio vs sunitinib: 0.57 HR, ASCO 2026 update

Peak · NCT05208047

Bezuclastinib + Sunitinib

Sunitinib 37.5 mg continuous

37.5 mg · ITT

GIST after imatinib (n = 209)

median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025

objective response rate (BICR): 26%, data cutoff 09.30.2025

Peak · NCT05208047

Imatinib 6

Imatinib

Imatinib 400 mg daily

400 mg · ITT

unresectable or metastatic KIT (CD117) positive GIST

median progression-free survival: 18.9 months, median follow up 37.5 months

median overall survival: 49 months, median follow up 37.5 months

best overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%)

Imatinib Phase 3 dose trials (combined analysis on label)

Imatinib

Imatinib 400 mg

400 mg · ITT

KIT (CD117) positive unresectable or metastatic GIST

Comparator: imatinib 600 mg

objective response rate (SWOG): 68.5%, up to 36 months

Imatinib Phase 2 (400 vs 600 mg)

Imatinib

Imatinib 600 mg

600 mg · ITT

KIT (CD117) positive unresectable or metastatic GIST

Comparator: imatinib 400 mg

objective response rate (SWOG): 67.6%, up to 36 months

Imatinib Phase 2 (400 vs 600 mg)

Imatinib

Imatinib 400 mg for 12 months

400 mg · ITT

resected primary GIST 3 cm or more

Comparator: placebo

recurrence-free survival hazard ratio vs placebo (interim): 0.4 HR, median follow up 15 months

recurrence-free survival hazard ratio vs placebo (updated): 0.72 HR, median follow up 50 months

Adjuvant Study 1 (ACOSOG Z9001) · NCT00041197

Imatinib

Imatinib 400 mg for 36 months

400 mg · ITT

resected high-risk KIT positive GIST

Comparator: imatinib for 12 months

recurrence-free survival hazard ratio, 36 vs 12 months: 0.46 HR, median follow up 42 months

overall survival hazard ratio, 36 vs 12 months: 0.45 HR, median follow up 48 months

Adjuvant Study 2 (SSG XVIII) · NCT00116935

NB003 2

NB003

NB003, 2L to 4L or later

not stated in source · Single arm

GIST 2L to 4L or later (n = 158)

objective response rate: 28.5%, data as of March 2025

median progression-free survival: 9.2 months, data as of March 2025

NB003 Phase 1 · NCT04936178

NB003

NB003, 3L subgroup

not stated in source · Single arm

GIST 3L (n not stated in source)

objective response rate: 46.7%, data as of March 2025

median progression-free survival: 13.7 months, data as of March 2025

NB003 Phase 1 · NCT04936178

Olverembatinib (HQP1351) 1

Olverembatinib (HQP1351)

Olverembatinib 30 to 50 mg every other day

30 to 50 mg · Single arm

SDH-deficient GIST (n = 26)

partial response as best response: 23.1%, cutoff 11.13.2025

median progression-free survival: 25.7 months, cutoff 11.13.2025

HQP1351SJ0003 · NCT03594422

Regorafenib 2

Regorafenib

Regorafenib 160 mg, 3 weeks on 1 off

160 mg · ITT

GIST after imatinib and sunitinib

Comparator: placebo

median progression-free survival: 4.8 months, primary analysis

progression-free survival hazard ratio vs placebo: 0.27 HR, primary analysis

median overall survival: 17.4 months, final OS analysis, 162 events

GRID · NCT01271712

Regorafenib

Placebo

placebo · ITT

GIST after imatinib and sunitinib

median progression-free survival: 0.9 months, primary analysis

median overall survival: 17.4 months, final OS analysis; 88% crossed over

GRID · NCT01271712

Ripretinib 4

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib, sunitinib and regorafenib

Comparator: placebo

median progression-free survival (BICR): 6.3 months, primary analysis

progression-free survival hazard ratio vs placebo: 0.15 HR, primary analysis

objective response rate (BICR): 9%, primary analysis

median overall survival: 15.1 months, not tested for significance

INVICTUS · NCT03353753

Ripretinib

Placebo

placebo · ITT

GIST after imatinib, sunitinib and regorafenib

median progression-free survival (BICR): 1 months, primary analysis

median overall survival: 6.6 months, 66% switched to ripretinib

INVICTUS · NCT03353753

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib (ITT n = 226)

Comparator: sunitinib 50 mg 4/2

median progression-free survival (IRR), ITT: 8 months, primary analysis

progression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significant

median progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysis

objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03

median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P

INTRIGUE · NCT03673501

Ripretinib

Sunitinib 50 mg 4/2

50 mg · ITT

GIST after imatinib (ITT n = 227)

median progression-free survival (IRR), ITT: 8.3 months, primary analysis

median progression-free survival, KIT exon 11 ITT: 7 months, primary analysis

objective response rate, KIT exon 11 ITT: 14.6%, primary analysis

median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratory

median PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory

INTRIGUE · NCT03673501

Sunitinib 2

Sunitinib

Sunitinib 50 mg, 4 weeks on 2 off

50 mg · ITT

GIST after imatinib progression or intolerance

Comparator: placebo

median time to tumor progression: 27.3 weeks, interim analysis

median progression-free survival: 24.1 weeks, interim analysis

objective response rate (partial responses): 6.8%, interim analysis

Study 1 · NCT00075218

Sunitinib

Placebo

placebo · ITT

GIST after imatinib progression or intolerance

median time to tumor progression: 6.4 weeks, interim analysis

median progression-free survival: 6 weeks, interim analysis

Study 1 · NCT00075218

Velzatinib (IDRX-42, GSK6042981) 2

Velzatinib (IDRX-42, GSK6042981)

Velzatinib 300 mg tablet (or 400 mg capsule), 2L

300 mg · Single arm

2L advanced GIST (n = 46)

median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025

objective response rate: 35%, cutoff 12.15.2025

StrateGIST 1 · NCT05489237

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.